Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. SFA_Sales_Revenues_May_2025_EN_espi.pdfSales revenues for May 2025

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 61 / 2025
Date of issue: 2025-06-20
Short name of the issuer
SOPHARMA AD
Subject
Sales revenues for May 2025
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
Sofia, Bulgaria, June 20, 2025 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for May 2025 the Company recorded decrease in sales of 1% compared to the same month of the previous year, incl. 10% increase in domestic sales and 8% decrease in export sales.
Annexes
File Description
SFA_Sales_Revenues_May_2025_EN_espi.pdf
SFA_Sales_Revenues_May_2025_EN_espi.pdf		 Sales revenues for May 2025

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2025-06-20 Ognian Donev Executive Director
20250620_121026_0802729360_SFA_Sales_Revenues_May_2025_EN_espi.pdf

Pobierz